Legal and financial questions of Pfizer-Novo-Metsera
Shareholder Primacy
00:00
How Cash Plus CVR Offers Work in Pharma M&A
Mike describes cash-plus-contingent-value-right deal structures and why earnouts are common in drug acquisitions.
Play episode from 06:58
Transcript
